• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (VigilVacCOVID Study)
ConclusionsOur study shows that mRNA-1273 had greater reactogenicity than BNT162b2. Overall, both vaccines had an adequate tolerability profile. mRNA-1273 vaccination caused fewer ARs with milder severity in SOTRs.
Source: BioDrugs - June 28, 2022 Category: Drugs & Pharmacology Source Type: research

What to Know About a Fourth COVID-19 Vaccine Dose
Most people ages 12 and older are considered “up to date” with their COVID-19 vaccines if they received either three doses of the mRNA shots from Pfizer-BioNTech or Moderna, or two doses of Johnson & Johnson’s Janssen vaccine. But some public health experts say another dose might be needed in the coming months. The Washington Post reports today that Pfizer and BioNTech soon plan to request authorization from the U.S. Food and Drug Administration (FDA) for a fourth dose of their vaccine in people ages 65 and older. In the past few days, Albert Bourla, Pfizer’s CEO, has said that he believes every...
Source: TIME: Health - March 15, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

A045 inadequate sars-cov-2 antibody response to mrna sars-cov-2 vaccine in adolescent kidney transplant recipients
Community spread of SARS-CoV-2 is waning with vaccination. It is unclear if kidney transplant recipients (KTR) remain at significant risk of contracting COVID19 due to inadequate antibody response. We investigated immunological parameters that could be associated with a blunted antibody response.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2021 Category: Allergy & Immunology Authors: L. Loop, C. Crane, C. Anterasian, B. Geng, E. Ingulli Source Type: research

Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients —a perspective
The recent coronavirus disease 2019 (COVID-19) pandemic raises serious concerns about potential prophylaxis and therapy in a naive population, particularly in patients with primary or secondary immunodeficiencies. The former mainly includes patients with defects in T-cell –mediated immunity and, to a lesser extent, those with antibody deficiencies and immune dysregulation. The latter includes patients undergoing therapy with immunosuppressive drugs, such as stem cell transplanted patients. In addition, patients with B-cell malignancies and autoimmune disorders trea ted with selected forms of targeted therapy (such as ant...
Source: Journal of Allergy and Clinical Immunology - May 11, 2020 Category: Allergy & Immunology Authors: Lennart Hammarstr öm, Hassan Abolhassani, Fausto Baldanti, Harold Marcotte, Qiang Pan-Hammarström Tags: Editorial Source Type: research